At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 240 enrolled
Drug / intervention
nab-paclitaxel IV +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Open-Label, Multi-Center Study to Assess Safety and Efficacy of Second/Third-Line Treatment With NAB®-Paclitaxel (ABI-007) In Combination With Epigenetic Modifying Therapy Of CC-486, Or Immunotherapy of Durvalumab (MEDI4736), Or As Monotherapy In Subjects With Advanced Non-Small Cell Lung Cancer (NSCLC): Abound.2L+
In Brief
A Phase 2 clinical trial evaluating nab-paclitaxel IV, CC-486, and 1 other intervention for Carcinoma, Non-Small-Cell Lung. Completed, enrolled 240 participants across 34 sites in 7 countries.
Detailed Summary
This is a Phase 2, open-label, multicenter study to assess the efficacy and safety of second/third-line treatment with nab-paclitaxel in combination with the epigenetic modifying therapy of CC-486 or immunotherapy of durvalumab, and nab-paclitaxel monotherapy in subjects with advanced non-small cell lung cancer (NSCLC).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCarcinoma, Non-Small-Cell Lung
CountriesCanada, France, Germany, Italy, Spain, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedSep 2014
Enrollment StartJan 2015
Primary CompletionJul 2017
Study CompletionAug 2023
TodayJul 2026
First PostedSep 26, 2014
Enrollment StartJan 7, 2015
Primary CompletionJul 17, 2017
Study CompletionAug 17, 2023
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 11.8 years ago
Interventions
nab-paclitaxel IVdrug
nab-Paclitaxel intravenous (IV) infusion
CC-486drug
Oral CC-486
Duravalumabdrug